Good day, and thank you for joining us. Yesterday, we issued a press release relating to the Phase III HARMONi-6 data ...
The use of IL-1 alpha and beta inhibition with ARCALYST has increasingly become the preferred treatment for recurrent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback